You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Claims for Patent: 10,624,855

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,624,855

Title:	Pharmaceutical composition, comprising phosphate binder particles
Abstract:	The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.
Inventor(s):	Laurent Chofflon, Erik Philipp
Assignee:	Vifor Fresenius Medical Care Renal Pharma Ltd
Application Number:	US15/039,633
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,624,855
Patent Claims:	1. A pharmaceutical composition for oral administration comprising: sucroferric oxyhydroxide particles; wherein at least 60% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm; wherein the d50 particle size distribution by volume of said sucroferric oxyhydroxide particles is in the range of 40 μm to 80 μm; wherein said pharmaceutical composition is in the form of a chewable tablet; wherein the chewable tablet has a disintegration time of less than 30 minutes as measured according to the European Pharmacopoeia 04/2011:20901; and wherein the weight of said chewable tablet is between 2000 mg and 3000 mg. 2. The pharmaceutical composition according to claim 1, further comprising at least one pharmaceutically acceptable excipient, and wherein at least 60% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 5 μm to 160 μm. 3. The pharmaceutical composition according to claim 2, wherein at least 80% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 5 μm to 160 μm. 4. The pharmaceutical composition according to claim 2, wherein the hardness of the chewable tablet is between 80 to 200 N as measured according to the European Pharmacopoeia 01/2008:20908. 5. The pharmaceutical composition according to claim 2, wherein the friability of the chewable tablet is between 0% to 7% as measured according to the European Pharmacopoeia 01/2010:20907. 6. The pharmaceutical composition according to claim 3, wherein the d50 particle size distribution by volume of said sucroferric oxyhydroxide particles is in the range of 42 μm to 75 μm. 7. The pharmaceutical composition according to claim 4, wherein the chewable tablet is formed by direct compression. 8. A pharmaceutical composition for oral administration comprising: about 2500 mg of sucroferric oxyhydroxide particles; wherein the d50 particle size distribution by volume of said sucroferric oxyhydroxide particles is in the range of 40 μm to 80 μm; wherein said pharmaceutical composition is in the form of a chewable tablet; and wherein the chewable tablet has a disintegration time of less than 30 minutes as measured according to the European Pharmacopoeia 04/2011:20901. 9. The pharmaceutical composition according to claim 8, wherein the hardness of the chewable tablet is between 80 to 200 N as measured according to the European Pharmacopoeia 01/2008:20908. 10. The pharmaceutical composition according to claim 9, wherein at least 60% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm. 11. The pharmaceutical composition according to claim 9, wherein at least 80% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm. 12. The pharmaceutical composition according to claim 9, wherein at least 90% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm. 13. The pharmaceutical composition according claim 11, wherein the d50 particle size distribution by volume of said sucroferric oxyhydroxide particles is in the range of 42 μm to 75 μm. 14. The pharmaceutical composition according to claim 11, wherein said chewable tablet is a compressed tablet. 15. The pharmaceutical composition according to claim 13, wherein said chewable tablet is formed by direct compression. 16. The pharmaceutical composition according to claim 11, wherein the friability of the tablet is between 0% to 7% as measured according to the European Pharmacopoeia 01/2010:20907. 17. The pharmaceutical composition according to claim 11, wherein the chewable tablet diameter is between 16 mm and 30 mm and the chewable tablet thickness is between 4.5 mm and 7.5 mm. 18. A pharmaceutical composition for oral administration comprising: sucroferric oxyhydroxide particles; wherein the d50 particle size distribution by volume of said sucroferric oxyhydroxide particles is in the range of 40 μm to 80 μm; wherein said pharmaceutical composition is in the form of a chewable tablet; wherein the weight of said chewable tablet is between 2000 mg and 3000 mg; wherein the chewable tablet has a disintegration time of less than 30 minutes as measured according to the European Pharmacopoeia 04/2011:20901; and wherein the sucroferric oxyhydroxide particles is more than 90% of the total weight of the chewable tablet (by weight on a dry weight basis). 19. The pharmaceutical composition according to claim 18, wherein the hardness of the chewable tablet is between 80 to 200 N as measured according to the European Pharmacopoeia 01/2008:20908. 20. The pharmaceutical composition according to claim 19, wherein at least 60% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm. 21. The pharmaceutical composition according to claim 19, wherein at least 80% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm. 22. The pharmaceutical composition according to claim 21, wherein at least 80% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 5 μm to 160 μm. 23. The pharmaceutical composition according claim 22, wherein the d50 particle size distribution by volume of said sucroferric oxyhydroxide particles is in the range of 42 μm to 75 μm. 24. The pharmaceutical composition according to claim 23, wherein said chewable tablet is a compressed tablet. 25. The pharmaceutical composition according to claim 23, wherein said chewable tablet is formed by direct compression. 26. The pharmaceutical composition according to claim 23, wherein the friability of the chewable tablet is between 0% to 7% as measured according to the European Pharmacopoeia 01/2010:20907. 27. The pharmaceutical composition according to claim 26, wherein the chewable tablet diameter is between 16 mm and 30 mm and the chewable tablet thickness is between 4.5 mm and 7.5 mm. 28. The pharmaceutical composition according to claim 19, wherein at least 90% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm. 29. The pharmaceutical composition according to claim 27, wherein at least 90% by volume of said sucroferric oxyhydroxide particles have a particle size within the range of 4 μm to 200 μm.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.